Synergy Pharmaceuticals Inc. (NASDAQ: SGYP) listed on NASDAQ in July 2008, headquartered in New York, New York (with research, technical operations and commercial offices in the suburbs of Philadelphia), with 291 full-time employees , Is a biopharmaceutical company focusing on the development and commercialization of new therapies for the treatment of gastrointestinal diseases and disorders. On December 12, 2018, Synergy Pharmaceuticals Inc. and its subsidiaries filed a voluntary petition for reorganization under Chapter 11 of the Bankruptcy Court for the Southern District of New York.
Synergy Pharmaceuticals (SGYP):
Synergy Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of new gastrointestinal (GI) therapies. The company is committed to science-driven innovation, providing patients and medical service providers with new treatment options, providing employees with opportunities for return, and creating excellent value for shareholders.
Synergy Pharmaceuticals pioneered the discovery, research and development of uroguanylin (a naturally occurring human gastrointestinal peptide) analogue for the treatment of gastrointestinal diseases and diseases. Synergy Pharmaceuticals discovered, is developing and controlling 100% global rights to the company’s proprietary urinary guanine-based GI platform, which includes a commercial stage product TRULANCE® (plecanatide) and a second major product candidate, dolcanatide.
The main product of Synergy Pharmaceuticals is plecanatide, a new gastrointestinal platform based on uroguanosine, commercialized under the name TRULANCE for the treatment of chronic idiopathic constipation and irritable bowel syndrome.
Synergy Pharmaceuticals has also developed dolcanatide to treat mild to moderate ulcerative colitis.
Synergy Pharmaceuticals signed a license agreement with Cipher Pharmaceuticals Inc. to develop, market, distribute and sell TRULANCE in Canada.